Skip to content
Screener

Interest Income at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$20.23M-18.1%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$6.25M+16.0%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$5M-16.7%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$2.65M-39.9%
Regenxbio logo
RegenxbioRGNX
$1.22M-63.8%
ALN
Alnylam PharmaceuticalsALNY
$28.14M+2.4%

Other financials

Income statement

See full
Revenue$218.3M+33.6%
Gross profit$214.4M+33.5%
Operating income$98.5M+231%
Net income$78.4M+1,442%
EPS (diluted)$0.30+1,400%

Balance sheet

See full
Cash & equivalents$156.4M+73.9%
Total debt$410.9M+59.9%
Total equity-$454.3M-7.8%
Total assets$557.9M+22.0%

Cash flow

See full
Operating cash flow$104.3M+153%
CapEx$209.0K+16.8%
Free cash flow$104.1M+153%

Valuation

See full
Market cap$2.38B+31.6%
Enterprise value$2.63B+33.4%
P/S2.5×-0.7×

Profitability

See full
Gross margin97.8%+0.8pp
Operating margin-33.3%-43.0pp
Net margin-40.9%-50.2pp
FCF margin39.7%

Returns & leverage

See full
Return on equity-882.8%
Debt / equity0.1×
Current ratio2.3×+0.1×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:InterestAndOtherIncome.

The source filing: BioCryst Pharmaceuticals’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:04 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-053300
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Total operating expenses119,785133,567977,796257,874
Income (loss) from operations98,46529,786(603,133)51,013
Other income (expense):
Interest income2,4342,5164,6905,540
Interest expense(21,712)(21,582)(41,491)(45,076)
Foreign currency gains (losses), net27(63)(198)(62)
Loss on extinguishment of debt(4,171)(4,171)
Other income (expense), net260(1,202)

Item 1. Financial Statements (Unaudited):

FAQ

What is BioCryst Pharmaceuticals's interest income?
BioCryst Pharmaceuticals (BCRX) reported interest income of $2.43M in Q2 2026.
How has BioCryst Pharmaceuticals's interest income changed year-over-year?
BioCryst Pharmaceuticals's interest income decreased by 3.3% year-over-year, from $2.52M to $2.43M.
What is the long-term trend for BioCryst Pharmaceuticals's interest income?
Over 3 years (2022 to 2025), BioCryst Pharmaceuticals's interest income has grown at a 27.7% compound annual growth rate (CAGR), from $5.13M to $10.67M.
What does interest income mean?
Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.

Ask your AI about BioCryst Pharmaceuticals's interest income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude